Glin4: Assessment of the Glycemic Responses to Nutritional Products
GLIN4
Determination of the Postprandial Glycemic Response and Glycemic Index of Nutritional Products: A Randomized Controlled Clinical Trial in Healthy Individuals
1 other identifier
interventional
12
1 country
1
Brief Summary
This study assesses the glycemic responses to nutritional products. During a study visit fasted subjects will consume one serving of the reference product or the test product. Capillary blood samples will be taken at baseline and at several time-points over a 2-hr period. Several nutritional products will be tested over time.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jan 2025
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2025
CompletedStudy Start
First participant enrolled
January 23, 2025
CompletedFirst Posted
Study publicly available on registry
January 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 4, 2025
CompletedMay 23, 2025
May 1, 2025
1 month
January 21, 2025
May 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The glycemic index of nutritional products
from enrollment to the end of treatment at about 9 weeks
Secondary Outcomes (2)
1. The postprandial glucose levels at each time point after each test product compared with the mean of the 3 references
from enrollment to the end of treatment at about 9 weeks
2. The postprandial incremental area under the curve (iAUC) after each test product compared with the mean of the 3 references
from enrollment to the end of treatment at about 9 weeks
Study Arms (10)
Arm 1
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 2
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 3
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 4
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 5
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 6
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 7
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 8
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 9
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Arm 10
OTHERAll subjects will receive all interventions during the trial. The order of the Nutritional products will be randomized.
Interventions
Plant-Based Oat Beverage with Sugar 1 (containing 25 grams of carbohydrates)
Plant-Based Oat Beverage with Sugar 2 (containing 25 grams of carbohydrates)
Plant-Based Oat Beverage with Sugar 3 (containing 25 grams of carbohydrates)
Plant-Based Oat Beverage with Sugar 4 (containing 25 grams of carbohydrates)
Plant-Based Oat Beverage No Sugar 1(containing 25 grams of carbohydrates
Plant-Based Oat Beverage No Sugar 2 (containing 25 grams of carbohydrates
High calorie, high protein oral powder nutritional supplement. (containing 25 grams of carbohydrates
Eligibility Criteria
You may qualify if:
- Age ≥ 18 and ≤ 65 years
- Body mass index (BMI) between 18.5 and 27 kg/m²
You may not qualify if:
- Baseline fasting Glucose ≥6.1 at screening visit
- Known history of gastrointestinal disease, bariatric surgery, AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), or any condition which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2)affect the results.
- Use of medications known to influence carbohydrate metabolism, gastrointestinal function or appetite, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or any medication which might, in the opinion of the medical director either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
- Major trauma or surgical event within 3 months of screening.
- Known intolerance, sensitivity or allergy to test products.
- Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
- History of cancer in the prior two years, except for non-melanoma skin cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Nutricia Researchlead
- INQUIS Clinical Researchcollaborator
Study Sites (1)
INQUIS Clinical Research, Ltd , 20 Victoria Street, 3rd Floor
Toronto, Ontario, M5C 2N8, Canada
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 21, 2025
First Posted
January 28, 2025
Study Start
January 23, 2025
Primary Completion
March 4, 2025
Study Completion
March 4, 2025
Last Updated
May 23, 2025
Record last verified: 2025-05
Data Sharing
- IPD Sharing
- Will not share